About: PARAMOUNT trial

An Entity of Type: cycling race, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

The PARAMOUNT trial is a clinical trial studying non-small-cell lung carcinoma (NSCLC). The trial was sponsored by Eli Lilly and Company and was conducted in several European countries and Canada. It was registered in November 2008 and was projected to end in September 2013. PARAMOUNT found that maintenance therapy with pemetrexed for patients with advanced non-squamous NSCLC was an effective and well-tolerated treatment option in those patients who had not had progress after initial therapy with pemetrexed plus cisplatin.

thumbnail
Property Value
dbo:abstract
  • The PARAMOUNT trial is a clinical trial studying non-small-cell lung carcinoma (NSCLC). The trial was sponsored by Eli Lilly and Company and was conducted in several European countries and Canada. It was registered in November 2008 and was projected to end in September 2013. PARAMOUNT found that maintenance therapy with pemetrexed for patients with advanced non-squamous NSCLC was an effective and well-tolerated treatment option in those patients who had not had progress after initial therapy with pemetrexed plus cisplatin. (en)
dbo:thumbnail
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 40417969 (xsd:integer)
dbo:wikiPageLength
  • 9677 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 994055599 (xsd:integer)
dbo:wikiPageWikiLink
dbp:b
  • no (en)
dbp:caption
  • text from a representative informed consent document (en)
dbp:commons
  • Category:PARAMOUNT trial (en)
dbp:d
  • no (en)
dbp:data
  • 939 (xsd:integer)
  • dbr:Eli_Lilly_and_Company
  • November 2008 (en)
  • June 2010 (en)
  • September 2013 (en)
  • PARAMOUNT, NCT00789373 (en)
dbp:display
  • the PARAMOUNT trial (en)
dbp:headerstyle
  • background:#ccf; (en)
dbp:label
  • start (en)
  • end (en)
  • other names (en)
  • sponsor (en)
  • number of participants (en)
  • primary completion (en)
dbp:labelstyle
  • background:#ddf; (en)
dbp:n
  • no (en)
dbp:q
  • no (en)
dbp:s
  • PARAMOUNT Eli Lilly Informed Consent Document (en)
dbp:species
  • no (en)
dbp:title
  • PARAMOUNT trial (en)
dbp:v
  • no (en)
dbp:voy
  • no (en)
dbp:wikiPageUsesTemplate
dbp:wikt
  • no (en)
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • The PARAMOUNT trial is a clinical trial studying non-small-cell lung carcinoma (NSCLC). The trial was sponsored by Eli Lilly and Company and was conducted in several European countries and Canada. It was registered in November 2008 and was projected to end in September 2013. PARAMOUNT found that maintenance therapy with pemetrexed for patients with advanced non-squamous NSCLC was an effective and well-tolerated treatment option in those patients who had not had progress after initial therapy with pemetrexed plus cisplatin. (en)
rdfs:label
  • PARAMOUNT trial (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License